Sun, Feb 1, 2015, 2:53 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • solantey@sbcglobal.net solantey Apr 17, 2013 11:23 AM Flag

    Bio-Tech Analyst Jason Napadano Values the Company At .24 Currently

    From today's Seeking Alpha article:

    In a previous article on Amarantus BioScience Holdings, Inc., I concluded that MANF was worth an estimated $42 million in value over at the Amarantus Therapeutics division given all the available scientific data. As such, I see the entire company worth an estimated $92 million. Given an estimated ~390 million share count, that equates to a target price of $0.24 per share. I expect the value of Amarantus to rise as investors become more familiar with LymPro and the company begins to generate the necessary data for a CLIA filing.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMBS
0.0815-0.0002(-0.24%)Jan 30 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.